On the Analysis of a Mathematical Model of CAR–T Cell Therapy for Glioblastoma: Insights from a Mathematical Model

Bodnar, Marek; Foryś, Urszula; Piotrowska, Monika J.; Bodzioch, Mariusz; Romero-Rosales, Jose A.; Belmonte-Beitia, Juan

doi:10.34768/amcs-2023-0027

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. Its success has led, in recent years, to its use being tested for different solid tumours, including glioblastoma, a type of primary brain tumour, characterised by aggressiveness and recurrence. This paper presents an analytical study of a mathematical model describing the competition of CAR-T and glioblastoma tumour cells, taking into account their immunosuppressive capacity. The model is formulated in a general way, and its basic properties are investigated. However, most of the analysis considers the model with exponential tumour growth, assuming this growth type for simplicity. The existence and stability of steady states are studied, and the subsequent focus is on two different types of treatment: constant and periodic. Finally, protocols for CAR-T cell therapy of glioblastoma are numerically derived; these are aimed at preventing the tumour from reaching a critical size and at prolonging the patients’ survival time as much as possible. The analytical and numerical results provide theoretical support for the treatment of glioblastoma using CAR-T cells.

References

Anderson, K., Stromnes, I. and Greenberg, P. (2017). Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies, Cancer Cell 31(3): 311–325.
Search in Google Scholar Back to article
Bodnar, M. and Piotrowska, M.J. (2016). Stability analysis of the family of tumour angiogenesis models with distributed time delays, Communications in Nonlinear Science and Numerical Simulation 31(1): 124–142.
Search in Google Scholar Back to article
Bodnar, M., Piotrowska, M.J. and Bogdańska, M.U. (2019). Mathematical analysis of a generalised model of chemotherapy for low grade gliomas, Discrete and Continuous Dynamical Systems B 24(5): 2149–2167, DOI: 10.3934/dcdsb.2019088.
Search in Google Scholar Back to article
Bodzioch, M., Bajger, P. and Foryś, U. (2021). Angiogenesis and chemotherapy resistance: Optimizing chemotherapy scheduling using mathematical modeling, Journal of Cancer Research and Clinical Oncology 147(8): 2281–2299, DOI: 10.1007/s00432-021-03657-9.
Search in Google Scholar Back to article
Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., Ostberg, J.R., Blanchard, M.S., Kilpatrick, J., Simpson, J., Kurien, A., Priceman, S.J., Wang, X., Harshbarger, T.L., D‘Apuzzo, M., Ressler, J.A., Jensen, M.C., Barish, M.E., Chen, M., Portnow, J., Forman, S.J. and Badie, B. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy, New England Journal of Medicine 375(26): 2561–2569, DOI: 10.1056/NEJMoa1610497.
Search in Google Scholar Back to article
Castellarin, M., Watanabe, K., June, C.H., Kloss, C.C. and Posey, A.D. (2018). Driving cars to the clinic for solid tumors, Gene Therapy 25(3): 165–175, DOI: 10.1038/s41434-018-0007-x.
Search in Google Scholar Back to article
Colli, P., Gomez, H., Lorenzo, G., Marinoschi, G., Reali, A. and Rocca, E. (2021). Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth, Mathematical Models and Methods in Applied Sciences 31(07): 1419–1468, DOI: 10.1142/S0218202521500299.
Search in Google Scholar Back to article
D’Agostino, M. and Raje, N. (2020). Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?, Leukemia 34(1): 21–34, DOI: 10.1038/s41375-019-0669-4.
Search in Google Scholar Back to article
de Pillis, L., Gu, W., Fister, K., Head, T., Maples, K., Murugan, A., Neal, T. and Yoshida, K. (2007). Chemotherapy for tumors: An analysis of the dynamics and a study of quadratic and linear optimal controls, Mathematical Biosciences 209(1): 292–315,
Search in Google Scholar Back to article
D’Errico, G., Machado, H.L. and Sainz Jr., B. (2017). A current perspective on cancer immune therapy: Step-by-step approach to constructing the magic bullet, Clinical and Translational Medicine 6(1): e3, DOI: abs/10.1186/s40169-016-0130-5.
Search in Google Scholar Back to article
Feins, S., Kong, W., Williams, E.F., Milone, M.C. and Fraietta, J.A. (2019). An introduction to chimeric antigen receptor (car) T-cell immunotherapy for human cancer, American Journal of Hematology 94(S1): S3–S9, DOI: 10.1002/ajh.25418.
Search in Google Scholar Back to article
Foryś, U. and Marciniak-Czochra, A.K. (2003). Logistic equations in tumour growth modelling, International Journal of Applied Mathematics and Computer Science 13(3): 317–325.
Search in Google Scholar Back to article
Garcke, H., Lam, K.-F. and Rocca, E. (2018). Optimal control of treatment time in a diffuse interface model of tumor growth, Applied Mathematics & Optimization 78: 495–544, DOI: 10.1007/s00245-017-9414-4.
Search in Google Scholar Back to article
Ghorashian, S., Kramer, A., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S.J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P.A., Mekkaoui, L., Cheung, G.W.-K., Pinner, D., Chu, J., Lucchini, G., Silva, J., Ciocarlie, O., Lazareva, A., Inglott, S., Gilmour, K.C., Ahsan, G., Ferrari, M., Manzoor, S., Champion, K., Brooks, T., Lopes, A., Hackshaw, A., Farzaneh, F., Chiesa, R., Rao, K., Bonney, D., Samarasinghe, S., Goulden, N., Vora, A., Veys, P., Hough, R., Wynn, R., Pule, M.A. and Amrolia, P.J. (2019). Enhanced car T cell expansion and prolonged persistence in pediatric patients with all treated with a low-affinity cd19 car, Nature Medicine 25(5): 1408–1414.
Search in Google Scholar Back to article
Hege, K.M., Bergsland, E.K., Fisher, G.A., Nemunaitis, J.J., Warren, R.S., McArthur, J.G., Lin, A.A., Schlom, J., June, C.H. and Sherwin, S.A. (2017). Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer, Journal for ImmunoTherapy of Cancer 5(1): 22, DOI: 10.1186/s40425-017-0222-9.
Search in Google Scholar Back to article
Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., Hernandez, J., Hung, F., Kaur, P., Teskey, G. and Tran, A. (2018). Immunotherapies: Exploiting the immune system for cancer treatment, Journal of Immunology Research 2018: 9585614, DOI: 10.1155/2018/9585614.
Search in Google Scholar Back to article
León-Triana, O., Perez-Martinez, A., Ramirez-Orellana, M. and Perez-Garcia, V. (2021). Dual-target CAR-TS with on- and off-tumour activity may override immune suppression in solid cancers: A mathematical proof of concept, Cancers 13(4): 703, DOI: 10.3390/cancers13040703.
Search in Google Scholar Back to article
Lima, E.A., Wyde, R., Sorace, A.G. and Yankeelov, T.E. (2022). Optimizing delivery of combination targeted and chemotherapy in a murine model of HER2+ breast cancer, Cancer Research 82(12 Supplement): 5050–5050, DOI: 10.1158/1538-7445.AM2022-5050.
Search in Google Scholar Back to article
Locke, F.L., Ghobadi, A., Jacobson, C.A., Miklos, D.B., Lekakis, L.J., Oluwole, O.O., Lin, Y., Braunschweig, I., Hill, B.T., Timmerman, J.M., Deol, A., Reagan, P.M., Stiff, P., Flinn, I.W., Farooq, U., Goy, A., McSweeney, P.A., Munoz, J., Siddiqi, T., Chavez, J.C., Herrera, A.F., Bartlett, N.L., Wiezorek, J.S., Navale, L., Xue, A., Jiang, Y., Bot, A., Rossi, J.M., Kim, J.J., Go, W.Y. and Neelapu, S.S. (2019). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial, The Lancet Oncology 20(1): 31–42.
Search in Google Scholar Back to article
Mahlbacher, G.E., Reihmer, K.C. and Frieboes, H.B. (2019). Mathematical modeling of tumor-immune cell interactions, Journal of Theoretical Biology 469: 47–60, DOI: 10.1016/j.jtbi.2019.03.002.
Search in Google Scholar Back to article
Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K.L., Martin, P.L., Nemecek, E.R., Yanik, G.A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B.L., Wood, P., Taran, T., Leung, M., Mueller, K.T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M.A. and Grupp, S.A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, New England Journal of Medicine 378(5): 439–448, DOI: 10.1056/NEJMoa1709866.
Search in Google Scholar Back to article
Miliotou, N.A. and Papadopoulou, C.L. (2018). CAR T-cell therapy: A new era in cancer immunotherapy, Current Pharmaceutical Biotechnology 19(1): 5–18.
Search in Google Scholar Back to article
Mostolizadeh, R., Afsharnezhad, Z. and Marciniak-Czochra, A. (2018). Mathematical model of chimeric anti-gene receptor (CAR) T cell therapy with presence of cytokine, Numerical Algebra, Control and Optimization 8(1): 63–80.
Search in Google Scholar Back to article
Pérez-García, V., Calvo, G., Bosque, J., León-Triana, O., Jiménez SĂňchez, J., Pérez Beteta, J., Belmonte-Beitia, J., Valiente, M., Zhu, L., García Gómez, P., Sánchez-Gómez, P., Miguel, E., Hortiguela, R., Azimzade, Y., Molina-García, D., Martínez-Rubio, A., Rojas, A., Ortiz de Mendivil, A., Vallette, F. and Vicente, A. (2020). Universal scaling laws rule explosive growth in human cancers, Nature Physics 16(12): 1–6, DOI: 10.1038/s41567-020-0978-6.
Search in Google Scholar Back to article
Pérez-García, V.M. and Pérez-Romasanta, L.A. (2015). Extreme protraction for low-grade gliomas: Theoretical proof of concept of a novel therapeutical strategy, Mathematical Medicine and Biology: A Journal of the IMA 33(3): 253–271, DOI: 10.1093/imammb/dqv017.
Search in Google Scholar Back to article
Pozzi, G., Grammatica, B., Chaabane, L., Catucci, M., Mondino, A., Zunino, P. and Ciarletta, P. (2022). T cell therapy against cancer: A predictive diffuse-interface mathematical model informed by pre-clinical studies, Journal of Theoretical Biology 547: 111172, DOI: 10.1016/j.jtbi.2022.111172.
Search in Google Scholar Back to article
Radunskaya, A., Kim, R. and Woods, T. (2018). Mathematical modeling of tumor immune interactions: A closer look at the role of a PD-l1 inhibitor in cancer immunotherapy, Spora: A Journal of Biomathematics 4: 25–41, DOI: 10.30707/SPORA4.1Radunskaya.
Search in Google Scholar Back to article
Sahoo, P., Yang, X., Abler, D., Maestrini, D., Adhikarla, V., Frankhouser, D., Cho, H., Machuca, V., Wang, D., Barish, M., Gutova, M., Branciamore, S., Brown, C.E. and Rockne, R.C. (2020). Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data, Journal of The Royal Society Interface 17(162): 20190734, DOI: 10.1098/rsif.2019.0734.
Search in Google Scholar Back to article
Sancho-Araiz, A., Mangas-Sanjuan, V. and Trocóniz, I.F. (2021). The role of mathematical models in immuno-oncology: Challenges and future perspectives, Pharmaceutics 13(7): 1016.
Search in Google Scholar Back to article
Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J.R., Fleury, I., Bachanova, V., Foley, S.R., Ho, P.J., Mielke, S., Magenau, J.M., Holte, H., Pantano, S., Pacaud, L.B., Awasthi, R., Chu, J., Anak, O., Salles, G. and Maziarz, R.T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, New England Journal of Medicine 380(1): 45–56, DOI: 10.1056/NEJMoa1804980.
Search in Google Scholar Back to article
Shah, N.N. and Fry, T.J. (2019). Mechanisms of resistance to CAR T cell therapy, Nature Reviews Clinical Oncology 16(6): 372–385, DOI: 10.1038/s41571-019-0184-6.
Search in Google Scholar Back to article
Stein, A.M., Grupp, S.A., Levine, J.E., Laetsch, T.W., Pulsipher, M.A., Boyer, M.W., August, K.J., Levine, B.L., Tomassian, L., Shah, S., Leung, M., Huang, P.-H., Awasthi, R., Mueller, K.T., Wood, P.A. and June, C.H. (2019). Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells, CPT: Pharmacometrics & Systems Pharmacology 8(5): 285–295, DOI: abs/10.1002/psp4.12388.
Search in Google Scholar Back to article
Stein, S., Zhao, R., Haeno, H., Vivanco, I. and Michor, F. (2018). Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients, PLOS Computational Biology 14(1): 1–24, DOI: 10.1371/journal.pcbi.1005924.
Search in Google Scholar Back to article
Stensjoen, A., Solheim, O., Kvistad, K., Haberg, A., Salvesen, O. and Berntsen, E. (2015). Growth dynamics of untreated glioblastomas in vivo, Neuro-Oncology 17(10): 1402–1411, DOI: 10.1093/neuonc/nov029.
Search in Google Scholar Back to article
Świerniak, A., Ledzewicz, U. and Schättler, H. (2003). Optimal control for a class of compartmental models in cancer chemotherapy, International Journal of Applied Mathematics and Computer Science 13(3): 357–368.
Search in Google Scholar Back to article
Wang, A.X., Ong, X.J., D’Souza, C., Neeson, P.J. and Zhu, J.J. (2023). Combining chemotherapy with CAR-T cell therapy in treating solid tumors, Frontiers in Immunology 14: 1140541, DOI: 10.3389/fimmu.2023.1140541.
Search in Google Scholar Back to article
Yabo, Y.A., Niclou, S.P. and Golebiewska, A. (2021). Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma, Neuro-Oncology 24(5): 669–682, DOI: 10.1093/neuonc/noab269.
Search in Google Scholar Back to article

On the Analysis of a Mathematical Model of CAR–T Cell Therapy for Glioblastoma: Insights from a Mathematical Model

Abstract

Paradigm

My account